We are a charity and rely on donations

Charity Number: 1117194 (England and Wales)

Registered Company: 06000961

Registered address:
Shift.ms, Platform, New Station Street, LS1 4JB, United Kingdom

London office:
Shift.ms, Somerset House, Strand, West Goods Entrance, London WC2R 1LA, United Kingdom

©2024 Shift.ms

@simonsays 

Last reply

simonsays

Results of Cladribine & Fingolimod tablet trials

Today at the American Association of Neurology results of 2 new tablet trials were shown. Neither drug is yet approved but this is a big step. Cladribine tablets taken 5 days/month for 2 months/year reduce relapses by 55% in a 2 year trial, i.e. the chance of a relapse drops from 39% to 20%.
1
@simonsays
@simonsays
 

Fingolimod tablets reduce relapse rate by 38-52% compared to beta-interferon (depending on the dose). This trial was for only one year and there were some serious infections on the higher dose of fingolimod. Both results are a big step forwards in the development of tablets to treat relapsing remitting MS.